New Data Shows Promising Shift in National Obesity Trends
A new Gallup National Health and Well-Being Index survey reveals that the growing use of injectable obesity treatments, such as Ozempic, Wegovy, Zepbound, and Mounjaro, is correlated with a measurable decline in U.S. obesity rates. According to the data, 37% of American adults are now classified as obese — down from a peak of 39.9% three years ago.
The survey highlights that 12.4% of respondents are currently using GLP-1 medications, more than double the 5.8% reported in February 2024. These drugs, first approved for obesity treatment in 2021, act on the brain and hormonal systems to reduce appetite and slow digestion, marking a new phase in the nation’s decades-long fight against obesity.
GLP-1 Medications: A Turning Point in Obesity Care
Experts describe GLP-1 agonists as a “watershed moment” in addressing obesity and related conditions such as diabetes. The survey recorded the highest-ever rate of diabetes at 13.8%, underscoring the urgency for effective weight management strategies. While public health campaigns and diet trends have struggled to reverse obesity growth in the past, GLP-1 drugs appear to be making an impact — albeit gradually.
Obesity rates have fallen most notably among adults aged 40 to 64, who are also the most frequent users of GLP-1 treatments. In this age group, the obesity rate dropped by five points to 42.8%. The survey also shows that women are using these medications at higher rates than men and report greater weight loss outcomes as a result.
Access and Affordability Remain Major Barriers
Despite their success, access to GLP-1 medications remains uneven. Dr. Fatima Cody Stanford, an obesity specialist at Harvard University, warned that many private insurers plan to discontinue coverage for these drugs in the coming year. Without insurance, patients could face costs of around $500 per month out of pocket.
Stanford noted that those with comprehensive coverage have seen the greatest benefits, but the anticipated loss of insurance support may limit broader public health impact. Drugmakers are currently developing oral pill versions of GLP-1 therapies, though affordability challenges are expected to persist even as these alternatives reach the market.
Slow but Encouraging Progress
While the decline in obesity rates is modest, researchers say it marks a pivotal shift after decades of steady increases. GLP-1 medications are helping many Americans achieve meaningful weight loss, potentially signaling the beginning of a new era in metabolic health. However, experts caution that sustained progress will depend on ensuring equitable access to these treatments and addressing underlying socioeconomic disparities in obesity care.